Obesity Clinical Trial
Official title:
Dietary Fiber: Is it the Missing Link in Achieving Long Term Behavior Change?
Verified date | March 2024 |
Source | Oklahoma State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overall objective of this three-arm randomized controlled trial is to compare a dietary fiber-focused behavioral intervention to standard weight loss education for improving eating-related behavior and cognition, weight, and metabolic markers of chronic disease risk in a population of adults with obesity.
Status | Active, not recruiting |
Enrollment | 63 |
Est. completion date | February 28, 2026 |
Est. primary completion date | January 31, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - 18-65 years of age - Dietary fiber intake =25 grams/day - Self-reported BMI =30 kg/m2 - Willingness to attend in-person education sessions - Willingness to avoid taking supplemental digestive aids (e.g., alpha-galactosidase (Beano®), - Willingness to provide informed consent. Exclusion Criteria: - Metabolic, digestive, or allergic conditions or reactions that preclude consumption of whole food or food groups (e.g., irritable bowel syndrome, diverticulosis) - History of gastric bypass surgery - Currently taking glucagon like glucagon-like peptide-1 (GLP-1) Receptor Agonists - Self-reported history of a diagnosed eating disorder - Chronic disease (other than obesity) - Pregnancy or lactation - Use of tobacco or electronic smoking products - Taking a pre-, pro-, or syn-biotic supplement - Enrollment in another weight loss or diet intervention |
Country | Name | City | State |
---|---|---|---|
United States | Oklahoma State University | Stillwater | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
Oklahoma State University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Body weight | Measure of body weight/mass | Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27) | |
Secondary | Body composition (fat mass, lean mass) | Dual x-ray absorptiometry (DEXA) scans | Measured at baseline (time 1, month 0) and post-observation (time 3, month 27) | |
Secondary | Fecal short chain fatty acids | Taken from fecal samples collected at home | Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27) | |
Secondary | Fecal bacteria measured using 16S ribosomal ribonucleic acid (rRNA) sequencing | Will include measures of diversity, abundance, etc. | Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27) | |
Secondary | Total Cholesterol | Measured via blood samples (unit= milligram/deciliter (mg/dL)) | Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27) | |
Secondary | Fasting blood glucose | Measured via blood samples (unit=mg/dL) | Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 33, month 27) | |
Secondary | Healthy Eating Index Scores measured using Health Eating Index 2020 (HEI-2020) | Taken from 3 day diet records (score range=0-100, higher=better diet quality) | Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27) | |
Secondary | Three-Factor Eating Questionnaire | Resulting scores in uncontrolled eating (range=9-36), cognitive restraint (range=3-12), and emotional eating (range=6-24); higher scores indicate more of that particular eating behavior | Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27) | |
Secondary | Implicit Association Test | Represented with a total D variable (No range, but more negative = greater preference for unprocessed food) | Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27) | |
Secondary | Behavioral Inhibition System/Behavioral Approach System (BIS/BAS) Scale | Score ranges from 20 to 80, with higher scores indicating greater behavioral inhibition and behavioral activation | Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27) | |
Secondary | Executive Function: Tower Test (Delis-Kaplan Executive Function System) | Total Achievement Score (range=0-30, higher = higher executive function) | Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27) | |
Secondary | Executive Function: Color-Word Interference Test (Delis-Kaplan Executive Function System) | Scaled inhibition/switching scores (score range=1-19, higher = higher executive function) | Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27) | |
Secondary | Skin Carotenoid scores measured via the Veggie Meter | Veggie Meter; score range 0-800 (higher=greater skin carotenoids (i.e., consumption of more fruits/vegetables) | Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27) | |
Secondary | High-density lipoprotein (HDL) cholesterol | Measured via blood samples (unit=mg/dL) | Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27) | |
Secondary | Low-density lipoprotein (LDL) cholesterol | Measured via blood samples (unit=mg/dL) | Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |